8,600-Person study probes contrave heart safety
Disease control
Ongoing
This study looks at whether the weight-loss medication Contrave (naltrexone/bupropion) increases the risk of serious heart problems like heart attacks, strokes, or heart-related death. About 8,600 obese or overweight adults with heart risk factors will be randomly assigned to tak…
Phase: PHASE4 • Sponsor: Currax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC